Shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Get Free Report) gapped down before the market opened on Tuesday. The stock had previously closed at $13.80, but opened at $12.97. LogicBio Therapeutics shares last traded at $12.92, with a volume of 3,302 shares changing hands.
LogicBio Therapeutics Price Performance
The company has a market capitalization of $594.50 million, a price-to-earnings ratio of -13.68 and a beta of 2.11. The stock’s 50-day simple moving average is $14.83 and its two-hundred day simple moving average is $10.57. The company has a quick ratio of 0.94, a current ratio of 1.43 and a debt-to-equity ratio of 0.29.
LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.25). The business had revenue of $32.20 million for the quarter, compared to the consensus estimate of $32.20 million.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc. was a biotechnology company focused on developing genomic medicines for rare diseases, particularly conditions affecting children. Its research centered on approaches intended to address the underlying genetic causes of disease. The company developed GeneRide, a genome-editing platform designed to integrate therapeutic genetic material into a patient’s DNA. Its lead program, LB-001, was investigated for methylmalonic acidemia, a rare inherited metabolic disorder. LogicBio also worked on sAAVy, a platform for discovering and developing adeno-associated virus vectors for gene delivery.
Recommended Stories
- Five stocks we like better than LogicBio Therapeutics
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
